fda category 2 bulk drug substances bpc-157 to Remove 12 Popular Peptides from the “Do Not Compound” List bpc 157 news fda bpc-157

I have been taking 1 or 2 more sprays than I should and have been experiencing itchiness all over...could this be the cause

Safety Profile: What Clinical Trials Actually Documented Across six clinical trials involving approximately 900 participants, AOD-9604 produced no treatment-related serious adverse events, no immunogenic response, no IGF-1 elevation, and no adverse cardiovascular or metabolic signals

23 After 6 months of supplementation, 74% in the B12 group had reached no aphthous ulcer status, compared with 32% in the placebo group

The FDAs final determination will follow separately, on a timeline the agency has not specified

Matthews JH

GI disorders like celiac disease and inflammatory bowel disease (IBD) reduce the bodys ability to absorb and maintain healthy B12 stores